PTC Eyes Transition From Capital-Raising To Money-Making Company

PTC Therapeutics, Inc. CEO Stuart Peltz told Scrip that with $1.1bn in the bank the company has never been better capitalized to fund its pipeline of rare disease drug candidates. And with royalties from Evrysdi (risdiplam) – newly approved in the US for spinal muscular atrophy (SMA) – and revenue from its existing commercial portfolio plus near- and mid-term product approvals, PTC forecasts that it may generate $1.5bn in revenue by 2023 and achieve profitability.

The company had $498.9m in cash as of 30 June, but then it received $650m in July from Royalty...